Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...
The tissue factor pathway inhibitor (TFPI) antagonist, given as a subcutaneous injection, has been cleared to prevent or reduce bleeding episodes in patients aged 12 years and older with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback